Navigating Clonal Hematopoiesis in Liquid Biopsy
Liquid biopsy (LBx) is a non-invasive genomic profiling approach that guides treatment selection and monitors resistance in cancer, especially when tumor tissue is limited.
However, distinguishing somatic variants from clonal hematopoiesis (CH)-derived variants is a key challenge, as CH variants can occur in prognostically important genes and confound variant interpretation.
Enhancing Liquid Biopsy Accuracy
MSK-ACCESS® powered with SOPHiA DDM™ enhances liquid biopsy accuracy by filtering CH variants, guiding precise cancer treatment decisions.
Fares (IUCT Oncopole, France) will explore real-world clinical cases where insights from MSK-ACCESS® powered with SOPHiA DDM™ helped inform treatment decisions.
Decentralized Liquid Biopsy Solution
The solution integrates matched white blood cell (WBC) DNA sequencing to filter out CH and germline variants, increasing confidence in the somatic origin of detected alterations.
Author's summary: Enhancing liquid biopsy with MSK-ACCESS® and SOPHiA DDM™.